Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor